Teleflex starts enrollment in BIOMAG-III pivotal trial of Freesolve resorbable magnesium coronary scaffold

Teleflex Incorporated

Teleflex Incorporated

TFX

0.00
  • Teleflex began patient enrollment in BIOMAG-III, a global pivotal trial of its Freesolve resorbable magnesium coronary scaffold.
  • Results have not been presented; the study is designed to generate data for future regulatory filings.
  • The trial will compare Freesolve with Abbott’s Xience drug-eluting stent to assess whether the scaffold can match standard stent outcomes.
  • Teleflex highlighted earlier research showing stable longer-term performance once the device has resorbed, supporting its strategy to move beyond permanent implants.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Teleflex Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260623597311) on June 23, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.